Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)

Authors :: Shuko Morita
K. Muro
Satoru Iwasa
Yinan Deng
Tomohiro Nishina
Tark Kim
Y.S. Park
J.B. Ahn
S.-W. Han
Yi Ba
Wei Wang
Sung-Bum Cho
Tao Zhang
R. Xu
Hiroyuki Uetake
Junichi Sakamoto
K-W. Lee
Kentaro Yamazaki
H. Matsumoto
Source :: Annals of Oncology. 28:x186
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
XELIRI
Bevacizumab
Colorectal cancer
business.industry
Hematology
medicine.disease
Second line chemotherapy
Non inferiority
Internal medicine
medicine
FOLFIRI
business
medicine.drug

Full Text Access

Tools